^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kangyueda (stapokibart)

    i
    Other names: CM310, CM 310, CM-310
    Associations

    News

    Trials
    Company:
    CSPC Pharma, Keymed Biosciences
    Drug class:
    IL-4Rα inhibitor
    Related drugs:
    Associations

    News

    Trials
    7d
    Exploration of the efficacy and safety of Stapokibart during the peri - operative period of type 2 sinusitis based on a clinical cohort study (ChiCTR2600116889)
    P=N/A, N=60, Recruiting, Jiangsu Provincial People's Hospital, The First Affiliated Hospital with NanJing Medical University; Jiangsu Provincial People's Hospital, The First A
    New trial
    |
    Kangyueda (stapokibart)
    7d
    Efficacy and Safety of Stapokibart (CM310) in Non-Allergic Rhinitis with Eosinophilia Syndrome (ESSNARES): An Investigator-initiated, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial (ChiCTR2500111463)
    P=N/A, N=90, Recruiting, Zhongnan Hospital of Wuhan University; Zhongnan Hospital of Wuhan University
    New trial
    |
    Kangyueda (stapokibart)
    7d
    Stapokibart in the Treatment of Perennial Allergic Rhinitis combined with Asthma: A Prospective, Single-Arm, Single-Center, Open-Label Study (ChiCTR2500109902)
    P4, N=34, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New P4 trial
    |
    Kangyueda (stapokibart)
    3ms
    ESSNARES: Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome (clinicaltrials.gov)
    P=N/A, N=90, Not yet recruiting, Huazhong University of Science and Technology
    New trial
    |
    Kangyueda (stapokibart)
    3ms
    Comprehensive Management Study of Domestic Innovative Biologic Therapy Combined with Surgery for Type 2 Chronic Rhinosinusitis with Nasal Polyps (ChiCTR2500108835)
    P=N/A, N=200, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    |
    Kangyueda (stapokibart)
    3ms
    A prospective, randomized, single-blind, self-controlled study evaluating the efficacy of endoscopic ethmoid infundibulum expansion surgery (EEIES) combined with Stapokibart in the treatment of type 2 chronic rhinosinusitis. (ChiCTR2500107337)
    P4, N=60, Recruiting, China-Japan Friendship Hospital of Jilin University; China-Japan Friendship Hospital of Jilin University
    New P4 trial
    |
    Kangyueda (stapokibart)
    4ms
    Study of CM310 in Adolescent Subjects With Atopic Dermatis (clinicaltrials.gov)
    P3, N=180, Active, not recruiting, Keymed Biosciences Co.Ltd | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Kangyueda (stapokibart)
    4ms
    Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis (clinicaltrials.gov)
    P3, N=180, Completed, Keymed Biosciences Co.Ltd | Not yet recruiting --> Completed | Trial completion date: May 2025 --> Jan 2025 | Trial primary completion date: May 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Kangyueda (stapokibart)
    5ms
    Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, First Affiliated Hospital of Chongqing Medical University
    New trial
    |
    Kangyueda (stapokibart)
    6ms
    Real-World Efficacy and Safety of STAPOKIBART in the Treatment of Moderate-to-Severe Atopic Dermatitis in Middle-Aged and Elderly Patients (ChiCTR2500107047)
    P=N/A, N=50, Not yet recruiting, Dematology Hospital of Southern Medical University; Dematology Hospital of Southern Medical University
    New trial • Real-world evidence
    |
    Kangyueda (stapokibart)
    6ms
    Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/ Metastatic HNSCC ( LONG'E ) (ChiCTR2500105767)
    P1, N=10, Not yet recruiting, Bejing Tongren Hospital, Capital Medical Uniersity; Bejing Tongren Hospital, Capital Medical Uniersity
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Anyouping (finotonlimab) • Kangyueda (stapokibart)
    8ms
    LONG'E: Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Beijing Tongren Hospital
    New P1 trial
    |
    Anyouping (finotonlimab) • Kangyueda (stapokibart)